About - ADTX :

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Employees - 47, CEO - Mr. Amro A. Albanna, Sector - Healthcare, Country - US, Market Cap - 2.18M

Altman ZScore(max is 10): -11.83, Piotroski Score(max is 10): 2, Working Capital: $-22280585, Total Assets: $29839281, Retained Earnings: $-162867941, EBIT: -30318994, Total Liabilities: $25390198, Revenue: $212107

- Current Price $0.19 - Analyst Target Price $2440.00

Stats & Key Metrics
TickerADTX
Index-
Curent Price 0.19
Change-17.65%
Market Cap2.18M
Average Volume3.13M
Income-46.25M
Sales0.21M
Book Value/Share8.87
Cash/Share0.03
Dividend Est-
Dividend TTM-
Dividend Ex-Date-
Employees47
Moving Avg 20days-42.99%
Moving Avg 50days-64.25%
Moving Avg 200days-99.63%
Shares Outstanding14.23M
Earnings Date-
Inst. Ownership0.05%
Key Ratios & Margins
Price/Earnings-
Forwad P/E-
PE Growth-
Price/Sales10.39
Price/Book0.02
Price/Cash6.61
Price/FCF-
Quick Ratio0.08
Current Ratio0.09
Debt/Equity2.18
Return on Assets-211.16%
Return on Equity-16400.32%
Return on Investment-871.94%
Gross Margin-572.37%
Ops Margin-14220.91%
Profit Margin-21803.99%
RSI16.25
BETA(β)1.07
From 52week Low-15.41%
From 52week High-99.95%
Earnings & Valuation
EPS-981.65
EPS next Year-
EPS next Qtr-
EPS this Year-
EPS next 5 Year-
EPS past 5 Year45.26%
Sales past 5 Year151.61%
EPS Y/Y88.52%
Sales Y/Y-71.70%
EPS Q/Q94.31%
Sales Q/Q-94.49%
Sales Surprise120.59%
EPS Surprise-
ATR(14)0.09
Perf Week-46.55%
Perf Month-45.09%
Perf Quarter-98.27%
Perf Year-99.90%
Perf YTD-99.93%
Target Price2440.00

AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer